HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.
暂无分享,去创建一个
Richard A. Loftus | F. Hecht | T. Elbeik | R. Grant | S. Deeks | M. Swanson | P. Cohen | R. Loftus | Tarek Elbeik | Frederick M. Hecht | Melinda Swanson | R. M. Grant
[1] D. Richman,et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. , 1998, JAMA.
[2] David A. Cooper,et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.
[3] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[4] J. Craig,et al. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. , 1998, AIDS.
[5] Morris Schambelan,et al. “Buffalo hump” in men with HIV-1 infection , 1998, The Lancet.
[6] K. Miller,et al. Visceral abdominal-fat accumulation associated with use of indinavir , 1998, The Lancet.
[7] Amalio Telenti,et al. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) , 1998, The Lancet.
[8] J. Rockstroh,et al. Reply: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. , 1997, AIDS.
[9] S. Hammer,et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. , 1998, The Journal of infectious diseases.
[10] P. Massip,et al. Impact of protease inhibitors on AIDS‐defining events and hospitalizations in 10 French AIDS reference centres , 1997, AIDS.
[11] M A Fischl,et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.
[12] Douglas D. Richman,et al. Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel , 1996 .
[13] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. , 1996, JAMA.
[14] T. Merigan,et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. , 1996, The New England journal of medicine.
[15] R. Schooley,et al. Antiretroviral Therapy for Adult HIV-lnfected Patients: Recommendations From a State-of-the-Art Conference , 1993 .
[16] K. Holmes,et al. Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients. , 1993, JAMA.
[17] R H Brook,et al. Efficacy, effectiveness, variations, and quality. Boundary-crossing research. , 1985, Medical care.